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Proton pump inhibitors enhance chemosensitivity, promote 
apoptosis, and suppress migration of breast cancer cells
Breast cancer is the most common cancer and is the leading 
cause of cancer deaths among women worldwide. Despite the 
availability of numerous therapeutics for breast cancer manage-
ment, cytotoxicity and emergence of drug resistance are major 
challenges that limit their benefits. The acidic microenvironment 
surrounding tumor cells is a common feature inducing cancer 
cell invasiveness and chemoresistance. Proton pump inhibitors 
(PPIs) are one of the most commonly prescribed drugs for the 
treatment of acid-related conditions. PPIs have been reported to 
exhibit antitumorigenic effects in many cancer types. In this 
study, the anti-proliferative and anti-migratory effects of PPIs in 
three breast cancer cell lines; MCF-7, T47D, and MDA-MB-231 
cells, have been investigated. In addition, the combined effects of 
PPIs with anticancer drugs, as well as the mechanism of PPI-
mediated anti-proliferative activity were evaluated. The anti-
proliferative and combined effects of PPIs were evaluated by 
MTT assay. Cell migration was assessed using the wound-heal-
ing assay. The mechanism of cell death was assessed using an-
nexin V-FITC/ propidium iodide staining flow cytometry method. 
Our results indicated that PPIs treatment significantly inhibited 
the growth of breast cancer cells in a dose-dependent manner. 
The antiproliferative activity of PPIs was significantly induced 
by apoptosis in all tested cell lines. The combined treatment of 
PPIs with doxorubicin resulted in a synergistic effect in all cell 
lines, whereas the combined treatment with raloxifene exhibited 
synergistic effect in T47D cells only and additive effects in MDA-
-MB-231 and MCF-7 cells. In addition, PPIs treatment signifi-
cantly reduced cell migration in MDA-MB-231 cells. In conclu-
sion, the addition of PPIs to the treatment regimen of breast 
cancer appears to be a promising strategy to potentiate the efficacy 
of chemotherapy and may suppress cancer metastasis.
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Breast cancer is the most common type of cancer among female worldwide (1). The 
incidence rates of breast cancer are increased with age in the majority of cases diagnosed 
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after the age of 40 years (2). Unfortunately, despite the continued development of many 
breast cancer therapies, toxicity and emerging of drug resistance are commonly encoun-
tered challenges (3). These phenomena are partly due to the highly heterogeneous nature 
of the disease at both inter-tumor and intra-tumor level (4).
There is accumulating evidence supporting the role of acidic tumor microenviron-
ment in tumor development and progression (5, 6). Metastasis, invasiveness, and chemo-
resistance have been shown to be associated with tumor acidic microenvironment (5–7). 
Moreover, extracellular acidity suppresses the activity of immune cells, like the cytotoxic 
T lymphocytes and natural killer cells protecting cancer cells from the immune system (8, 
9). The deviant extracellular acidity is maintained by the overexpression of different ion/ 
proton pumps including the vacuolar-H+-ATPase (V-ATPase) pumps, which extrude intra-
cellular protons to the extracellular space. Thus, targeting such pump has been considered 
as a promising strategy to deteriorate cancer cells and reduce tumor metastasis (10).
Numerous pharmacological agents have been used to inhibit the activity of the V-
ATPase pump; however, the clinical application is limited due to their cytotoxicity to nor-
mal cells (10). Proton pump inhibitors (PPIs), such as lansoprazole and omeprazole, are the 
most frequently prescribed drugs for the treatment of acid-related disorders. They spe-
cifically target the gastric proton pump (H+, K-ATPase pump) that is located in the gastric 
parietal cells (11). PPIs also act as V-ATPase inhibitors, suggesting that they may affect the 
tumor acidic microenvironment (10). In fact, they have been shown to inhibit cancer pro-
gression and metastasis and reduce drug resistance in several types of cancers including 
breast, gastric, colorectal, esophageal, and pancreatic cancers (12–16).
Interestingly, it was initially suggested that the anticancer effect of PPIs is primarily 
related to their ability to block the V-ATPase pump (10). However, several other mecha-
nisms that contribute to their anticancer activity have been proposed and investigated 
including suppression of the Wnt/β-catenin (17), mammalian target of rapamycin (mTOR), 
hypoxia-inducible factor 1-alpha (HIF-1 α), and others (15, 18, 19).
In the current study, the effects of different PPIs on the viability, migration, and apop-
tosis of breast cancer cell lines of different molecular subtypes were evaluated. The ability 
of PPIs to enhance the antitumor effect of other anticancer drugs was also assessed as well 
as the underlying molecular mechanism driving the antiproliferative effect of PPIs.
EXPERIMENTAL
Chemicals
Lansoprazole, omeprazole, pantoprazole, and raloxifene were purchased from Sigma-
Aldrich (USA) as powder and dissolved in DMSO. They were further diluted with Dul-
becco’s Modified Eagle Medium to reach the desired final concentrations immediately 
before use. Doxorubicin hydrochloride was purchased from Ebewe Untrerach (Austria) as 
a solution at a concentration of 2 mg mL–1. MTT (3-[4,5-dimethylthiazol-2-yl]-diphenyltet-
razolium bromide) was purchased from Sigma-Aldrich (USA).
Cell lines
Human MDA-MB-231, MCF-7, and T47D breast cancer cell lines were obtained from 
the American Type Culture Collection (ATCC) (USA). These cells were maintained in high 
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glucose Dulbecco’s Modified Eagle Medium (DMEM) (Eurobio, French) supplemented 
with 10 % fetal bovine serum (FBS), 100 U mL–1 penicillin, 100 μg mL–1 streptomycin, and 
2 mmol L–1 l-glutamine and were incubated at 37 °C in a 95 % humidified air of 5 % CO2.
Cell viability assay
In order to evaluate cell viability, the MTT (3-[4,5-dimethylthiazol-2-yl]-diphenyltet-
razolium bromide) colorimetric assay was performed as previously described (20). Briefly, 
T47D, MCF-7, and MDA-MB-231 cells were plated in a 96-well plate at a seeding density of 
8,000, 7,000, 5000 cells per well, respectively. After 24 h, they were treated with different 
concentrations of PPIs, doxorubicin, and raloxifene alone or in combination. After 48 h, 
MTT was added at a working concentration of 5 mg mL–1 and incubated for 3 h. Media 
were then aspirated, and formazan crystals were solubilized in DMSO. The optical den-
sity was measured at 570 nm using the Synergy HTX Multi-Mode Microplate Reader 
(BioTek Instruments, Winooski, VT, USA). The percentage of cell viability was calculated 
according to the following equation: 
cell viability (%) = (optical density of treated cells/optical density of untreated cells) × 100
Migration assay
MDA-MB-231 cells were plated at a seeding density of 15,000 cells per insert well 
(Ibidi, Germany) and incubated overnight to grow to confluency. Afterward, inserts were 
removed, and cells were treated with 10 μg mL–1 of mitomycin C for 2 h. Cells were treated 
with PPIs at half the IC50 concentration. Images were captured at 0 and 24 h using a micro-
scope (BOECO, Germany) coupled with the 5.0 Mega Cmos camera at the magnification of 
4 .́ Cell migration was determined by measuring the wound width using ImageJ software.
Flow cytometry analysis of apoptosis
Cells were plated in 6-well plates at 4 × 105 cells per well for T47D and MCF-7 cells and 
3 × 105 cells per well for MDA-MB-231 cells. On the following day, cells were treated with 
either double IC50 concentration of lansoprazole or doxorubicin as a positive control and 
incubated for 48 h. Detached cells were collected, combined with the trypsinized attached 
cells, and centrifuged at 1400 RPM, 4 °C, for 10 min. The cell pellet was resuspended in 200 
μL cold 1X binding buffer, and cells were stained with 5 μL Annexin V-FITC and incu-
bated for 5 min at room temperature. Propidium iodide was then added to each tube and 
analyzed immediately. The analysis was performed on BD FACSCanto II flow cytometer 
(BD Biosciences, USA) using BD FACSDiva software.
Statistical analysis 
Data analysis was performed using GraphPad Prism software version 7. The differ-
ences between treatments groups were determined by t-test or one-way analysis of vari-
ance (ANOVA) followed by Tukey post hoc t-test as appropriate. Data were expressed as 
mean ± SD and p < 0.05 was considered a statistically significant difference. A non-linear 
regression analysis was used to calculate IC50 values. The effect of combined treatment of 
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PPIs and anticancer agents was evaluated by calculating the combination index (CI) value 
using CompuSyn software based on Chou-Talalay's Combination Index Theorem (21). CI 
values < 1, =1, and > 1 indicate synergism, additive, and antagonistic effects, respectively. 
CI values were calculated by using the following equation:
 CI = (D1/Dx1) + (D2/Dx2)
where (Dx)1= dose of drug 1 to produce 50 % cell killing alone, (D)1 = dose of drug 1 to 
produce 50 % cell killing in combination with (D)2, (Dx)2 = dose of drug 2 to produce 50 % cell 
killing alone, and (D)2 = dose of drug 2 to produce 50 % cell killing in combination with (D)1.
RESULTS AND DISCUSSION
The effect of PPIs treatment on the migration of breast cancer cells
To examine the effect of PPIs on the migration of MDA-MB-231 cells, wound healing 
assay was performed. As can be noted in (Fig. 1a), complete closure of the wound was 
observed in the control sample. However, exposure to PPIs treatment significantly inhib-
Fig. 1. Effect of PPIs treatment on MDA-MB-231 cells migration: a) images of the wound at the begin-
ning and after 24 h of the treatment period (magnification 4x); b) quantitative analysis of wound 
closure relative to wound distance at time 0. The experiment was performed in duplicate and the data 
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ited the migration of MDA-MB-231 cells by 67, 69 and 68 % for lansoprazole, omeprazole, 
and pantoprazole, respectively (Fig. 1b).
The V-ATPase expression is strongly associated with the invasive and metastatic ca-
pabilities of cancer cells. This was shown to be due to the acidic microenvironment that 
facilitates the optimal activation and secretion of proteases (22). Many studies have shown 
that breast cancer cells including MDA-MB-231, MCF-7, and T47D overexpress V-ATPases 
pumps. However, the activity of this pump appears to be augmented in highly metastatic 
cells like MDA-MB-231 relative to the poorly metastatic cells like MCF-7 (22, 23). Many 
pharmacological agents have been used as V-ATPase pump inhibitors like bafilomycin A1 
and concanamycin. However, these agents exhibited high cytotoxicity to normal cells as 
well as to cancer cells. In contrast, PPIs are known to directly inhibit V-ATPase pumps and 
selectively target cancer cells (24).
The antiproliferative effect of PPIs in different molecular subtypes of breast cancer
The antiproliferative effects on different molecular subtypes of breast cancer cells 
treated with various doses of PPIs (lansoprazole, omeprazole, and pantoprazole) are 
shown in (Fig. 2). According to the results, the growth of breast cancer cells was signifi-
cantly inhibited after PPIs treatment for 48 h compared to the control, in a dose-dependent 
manner. Interestingly, the observed antiproliferative effect of PPIs significantly varied be-
tween the three examined cell lines with T47D cells being the most responsive to PPIs 
treatment, whereas MDA-MB-231 cells were the least responsive cells. In contrast, the vi-
ability of normal fibroblast cells was not affected compared to the control group (IC50 > 3000 
μmol L–1). On the other hand, lansoprazole appears to be more effective in cancer growth 
inhibition than omeprazole and pantoprazole. The IC50 values for PPIs treatment were 
129–299, 201–51 and 256–645 μmol L–1 in T47D, MCF-7, and MDA-MB-231 cells, respec-
tively (Table I).




Lansoprazole 129.0 ± 9.8 201.0 ± 9.1 256.5 ± 4.3
Omeprazole 222.4 ± 8.8 349.3 ± 23.7 395.6 ± 7.2
Pantoprazole 299.6 ± 21.6 514.4 ± 25.9 645.9 ± 8.2
Doxorubicin 1.9 ± 0.2 0.9 ± 0.1 2.0 ± 0.2
Raloxifene 27.3 ± 1.9 32.9 ± 1.3 25.0 ± 2.1
a mean ± SD
PPIs enhanced apoptosis in breast cancer cells
In order to determine if the anti-proliferative effect of PPI on the cells was due to the 
induction of apoptosis or necrosis, flow cytometric analyses of cells stained for annexin V or 
DNA fragmentation were performed. Following 48 h incubation period with the  IC50 con-
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centration of lansoprazole, the percentages of apoptosis and necrosis were examined. As 
shown in (Fig. 3), exposure to PPIs significantly increased apoptosis by more than 50 % in 
the three cell lines examined. On the other hand, the percentages of necrosis were not sig-
nificantly affected.
According to De Milito et al. (25), omeprazole and esomeprazole showed an apoptotic 
effect in the human B cell line, which was mediated through a caspase-independent mecha-
nism. In another study, by Scaringi et al. (26), omeprazole induced apoptosis in a time dose-
dependent manner in Jurkat cells (T-cells). In the latter cells, apoptosis was dependent on 
caspases and cysteine cathepsins. Interestingly, Zhang et al. (27), reported that lansoprazole 
significantly induced apoptosis in breast cancer cells through the ability to provoke cytosolic 
acidification, lysosomal alkalinization, and reactive oxygen species (ROS) accumulation. 
Fig. 2. Antiproliferative effects of PPIs treatment on cell viability of breast cancer cells in: a) T47D, 
b) MCF-7, c) MDA-MB-231. Data shown represent the mean percentages of cell viability ± SD. Each 
experiment was performed in triplicate in three independent experiments (N = 3). *p < 0.05 signifi-
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 Further investigation into the different possible signaling pathways should shed light on the 
mechanism through which PPIs exert their apoptosis induction effect.
Effects of combined treatment of PPIs and anticancer agents on the viability of breast 
cancer cells
Doxorubicin is one of the most effective chemotherapeutic agents that is widely used 
in breast cancer treatment as well as for the treatment of other types of cancer such as lung, 
multiple myeloma, and thyroid cancers. It induces cytotoxicity effects through inhibition 
Fig. 3. Lansoprazole induces apoptosis in breast cancer cells. Breast cancer cells treated with lansopra-
zole for 48 h then stained with annexin V-FITC/ PI and analyzed by flow cytometry: a) dot plot for an-
nexin V-FITC/ PI staining, where Q3 showed viable cells, Q1 necrotic cells, Q2 late apoptotic, and Q4 
early apoptotic and percentages of alive cells, apoptotic cells and necrotic cells in T47D, b) MCF-7, 
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Fig. 4. Effect of anticancer agents on the growth of breast cancer cells: a) antiproliferative effects of 
doxorubicin treatment on cell viability of breast cancer cells, b) antiproliferative effects of raloxifene 
treatment on cell viability of breast cancer cells. Data shown represent the mean percentages of cell 
viability ± SD. Each experiment was performed in triplicate in three independent experiments (N = 
3). * p < 0.05 significantly different from control groups.
of topoisomerase II or free radical generation. However, the cytotoxic effects of doxorubi-
cin on various organs and tumor resistance limit its clinical usefulness (28). Patel et al. (29), 
reported that pretreatment with PPIs increased tissue penetration of doxorubicin in multi-
layered cell cultures and enhanced its distribution from blood vessels in solid tumors.
Raloxifene, on the other hand, is a second-generation selective estrogen receptor mod-
ulator (SERM) that induces estrogen antagonist effect on breast tissues (30). FDA has ap-
a)                                                                 b)
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Fig. 5. Effect of combined treatment of lansoprazole and anticancer agents on the growth of breast 
cancer cells: a) effects of combined treatment of lansoprazole and doxorubicin on the growth of breast 
cancer cells after 48 h of treatment, b) effects of combined treatment of lansoprazole and raloxifene 
on the growth of breast cancer cells after 48 h of treatment. Data shown represent the mean percent-
ages of cell viability ± SD. Each experiment was performed in duplicate in three independent experi-
ments (N = 3). * p < 0.05 significantly different from respective anticancer agents treatment alone.
proved raloxifene for the prevention and treatment of invasive ER-positive breast cancer 
in postmenopausal women. The beneficial role of combined treatment is the possibility to 
enhance the cytotoxic effect of chemotherapeutic agents by reducing the drug resistance 
and, consequently, allowing the use of lower concentrations of drugs while maintaining 
the same effectiveness.
The ability of PPIs to enhance the cytotoxic effects of the anticancer agents, doxorubi-
cin and raloxifene, on breast cancer cells was then evaluated. First, the IC50 of both drugs 
on the three cell lines were determined. Exposure of cells to increasing concentrations of 
doxorubicin ranged from 0.3 to 5 μmol L–1 significantly inhibited the growth of breast 
cancer cells in a dose-dependent manner (Fig. 4a). The IC50 values for doxorubicin were 1.9, 
0.9, and 2.0 μmol L–1 in T47D, MCF-7, and MDA-MB-231 cells, respectively. Similarly, the 
survival of cells was significantly inhibited by raloxifene treatment at the concentration 
a)                                                                 b)
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range 3–100 μmol L–1 in a dose-dependent manner (Fig. 4b) with IC50 values 27.3, 32.9, and 
25.0 μmol L–1 in T47D, MCF-7, and MDA-MB-231 cells, respectively. Our results demon-
strated that the combination of PPIs and doxorubicin significantly increased the cytotoxic 
effect of doxorubicin and resulted in synergistic inhibition of growth in MDA-MB-231, 
MCF-7, and T47D cells (CI < 1) (Table II). However, variable results were obtained when 
PPIs were combined with raloxifene. In T47D cells, combining PPIs to raloxifene signifi-
cantly suppressed cell growth compared to respective raloxifene treatment alone with CI 
values < 1. Interestingly, combined treatment of raloxifene and PPIs in MDA-MB-231 and 
MCF-7 cells rather demonstrate the additive effect. Thus, the combined effect of PPIs and 
anticancer drugs is variable and may be affected by the type of cancer cells, anticancer 
agents, and probably the mechanism that is responsible for drug resistance in the different 
cell lines.
CONCLUSIONS
PPIs (lansoprazole, omeprazole, and pantoprazole) inhibited the growth of MDA-
MB-231, MCF7, and T47D breast cancer cells in a dose-dependent manner. This anti-proli-
ferative activity is mediated through the induction of apoptosis. Combined PPIs with 
doxorubicin resulted in synergistic inhibition of viability in three cell lines, but the  combined 
effect with raloxifene induced a synergistic effect in T47D cells with only additive effect in 
MDA-MB-231 and MCF-7 cells. In MDA-MB-231 cells, PPIs treatment also significantly 
inhibited cell migration.
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